Association Between Discharge Medications and Oncologic Post‐Embolization‐Syndrome‐Related Outcomes
Cancer Medicine · 2025
DOI: 10.1002/cam4.71418 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Hanzhou Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Imaging Sciences, Emory School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Patient Discharge, Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Harvey L. Neiman Health Policy Institute.
Abstract (Originalsprache)
Background
Post‐embolization syndrome after transarterial chemoembolization (TACE) and Yttrium‐90 radioembolization (TARE) causes significant morbidity. Understanding whether discharge prescriptions influence short‐term outcomes may guide standardized pain‐management strategies.
Methods
A retrospective cohort study of 3191 patients (3988 procedures) with hepatocellular carcinoma from the Merative MarketScan Databases (2009–2022) was performed. The composite outcome was 7‐day drug escalation or hospital readmission. Bivariate logistic regression identified candidate variables ( p < 0.10); multivariable logistic regression with patient‐clustered robust standard errors estimated adjusted odds ratios (aORs), adjusting for age, sex, and Charlson Comorbidity Index (CCI).
Results
Compared to patients discharged without opioids post‐chemoembolization, those prescribed opioids at discharge had 83% lower odds of experiencing drug escalation or readmission (odds ratio [aOR] = 0.17, p < 0.001), and those undergoing radioembolization had 59% lower odds (aOR = 0.41, p < 0.001). Being prescribed antiemetics or steroids was also associated with lower odds of escalation/readmission events, with percentages varying by procedure type.
Conclusions
Prescribing opioids, along with antiemetics and steroids, at discharge may reduce the likelihood of post‐procedural events, such as drug escalation and readmission, in patients undergoing trans‐arterial chemoembolization and radioembolization for hepatocellular carcinoma. These findings highlight the importance of a comprehensive pain management strategy in interventional oncology and warrant consideration in clinical practice guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology and Imaging Sciences, Emory School of Medicine, Atlanta, Georgia, USA.
- Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Health Promotion and Policy, School of Public Health and Health Sciences, University of Massachusetts Amherst, Amherst, Massachusetts, USA.
- Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
- University of Toronto, Institute of Health Policy, Management and Evaluation, Toronto, Ontario, Canada.
- Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
ORCID-Profile: Hanzhou Li, Nicholas Lima
Förderung
- Harvey L. Neiman Health Policy Institute
Zitieren
APA
Li, H., Moon, J., Sim, N., Horný, M., Lima, N., Konstantinidis, M., Iyer, D., Benenati, S., Gichoya, J., Newsome, J., & Bercu, Z. (2025). Association Between Discharge Medications and Oncologic Post‐Embolization‐Syndrome‐Related Outcomes. Cancer Medicine. https://doi.org/10.1002/cam4.71418
Vancouver
Li H, Moon J, Sim N, Horný M, Lima N, Konstantinidis M, et al. Association Between Discharge Medications and Oncologic Post‐Embolization‐Syndrome‐Related Outcomes. Cancer Medicine. 2025. doi:10.1002/cam4.71418
BibTeX
@article{Li2025,
author = {Li, Hanzhou and Moon, John and Sim, Nathan and Horný, Michal and Lima, Nicholas and Konstantinidis, Menelaos and Iyer, Deepak and Benenati, Sonia and Gichoya, Judy and Newsome, Janice and Bercu, Zachary},
title = {Association Between Discharge Medications and Oncologic Post‐Embolization‐Syndrome‐Related Outcomes},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71418}
}
EUVIMED